Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a business update conference call and webcast scheduled for Tuesday, April 15, 2025, at 4:30 p.m. ET. The company, which focuses on developing therapeutic biologics for cancer and autoimmune disease treatment through selective T cell engagement and modulation, will make the presentation available to investors through multiple channels.
Access details include:
- Domestic investors: 1-844-826-3035
- International investors: 1-412-317-5195
- Conference ID: 10199037
Cue Biopharma (Nasdaq: CUE), un'azienda biofarmaceutica in fase clinica, ha annunciato una conferenza telefonica e webcast di aggiornamento aziendale programmata per martedì 15 aprile 2025, alle 16:30 ET. La società, che si concentra sullo sviluppo di biologici terapeutici per il trattamento di tumori e malattie autoimmuni tramite l'engagement e la modulazione selettiva delle cellule T, renderà la presentazione disponibile agli investitori attraverso diversi canali.
I dettagli per l'accesso includono:
- Investitori nazionali: 1-844-826-3035
- Investitori internazionali: 1-412-317-5195
- ID conferenza: 10199037
Cue Biopharma (Nasdaq: CUE), una empresa biofarmacéutica en etapa clínica, ha anunciado una llamada y webcast de actualización empresarial programada para el martes 15 de abril de 2025 a las 4:30 p.m. ET. La compañía, que se enfoca en desarrollar biológicos terapéuticos para el tratamiento del cáncer y enfermedades autoinmunes mediante la activación y modulación selectiva de células T, pondrá la presentación a disposición de los inversores a través de varios canales.
Los detalles de acceso incluyen:
- Inversores nacionales: 1-844-826-3035
- Inversores internacionales: 1-412-317-5195
- ID de conferencia: 10199037
Cue Biopharma (나스닥: CUE)는 임상 단계의 바이오제약 회사로, 2025년 4월 15일 화요일 오후 4시 30분(동부시간)에 기업 업데이트 컨퍼런스 콜 및 웹캐스트를 개최한다고 발표했습니다. 이 회사는 선택적 T 세포 관여 및 조절을 통해 암 및 자가면역 질환 치료를 위한 치료용 생물학제를 개발하는 데 주력하고 있으며, 발표 자료를 여러 채널을 통해 투자자들에게 제공할 예정입니다.
접속 정보는 다음과 같습니다:
- 국내 투자자: 1-844-826-3035
- 국제 투자자: 1-412-317-5195
- 컨퍼런스 ID: 10199037
Cue Biopharma (Nasdaq : CUE), une entreprise biopharmaceutique en phase clinique, a annoncé une conférence téléphonique et un webcast de mise à jour commerciale prévus pour mardi 15 avril 2025 à 16h30 ET. La société, qui se concentre sur le développement de biologiques thérapeutiques pour le traitement du cancer et des maladies auto-immunes via l'engagement et la modulation sélective des cellules T, mettra la présentation à disposition des investisseurs par plusieurs canaux.
Les informations d'accès incluent :
- Investisseurs nationaux : 1-844-826-3035
- Investisseurs internationaux : 1-412-317-5195
- ID de la conférence : 10199037
Cue Biopharma (Nasdaq: CUE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat eine Telefonkonferenz und ein Webcast zur Unternehmensaktualisierung für Dienstag, den 15. April 2025, um 16:30 Uhr ET angekündigt. Das Unternehmen, das sich auf die Entwicklung therapeutischer Biologika zur Behandlung von Krebs und Autoimmunerkrankungen durch selektive T-Zell-Aktivierung und -Modulation spezialisiert hat, wird die Präsentation Investoren über verschiedene Kanäle zugänglich machen.
Zugangsdaten umfassen:
- Inländische Investoren: 1-844-826-3035
- Internationale Investoren: 1-412-317-5195
- Konferenz-ID: 10199037
- None.
- None.
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET.
Conference Call and Webcast Details
Tuesday, April 15 at 4:30 p.m. ET
| Investors: | 1-844-826-3035 |
| International Investors: | 1-412-317-5195 |
| Conference ID: | 10199037 |
| Webcast Link: | https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 |
The live and archived webcast will also be available in the Investors and Media section of the Company’s website. The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
When is Cue Biopharma's (CUE) upcoming business update call in April 2025?
How can investors access Cue Biopharma's (CUE) April 2025 business update webcast?
What is the dial-in number for international investors for CUE's April 2025 update call?
How long will Cue Biopharma's (CUE) April 2025 business update webcast be available?
What therapeutic areas does Cue Biopharma (CUE) focus on developing treatments for?
